Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Rocket Lab USA Inc (RKLB) Price & Performance

Novavax IncTrade
Rocket Lab USA IncTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Rocket Lab USA Inc — how do they compare? Novavax Inc trades at $8.09 (market cap $1.30B), while Rocket Lab USA Inc trades at $72.54 (market cap $41.08B). The key difference: Rocket Lab USA Inc is far larger — about 31.6× Novavax Inc's market cap. Which is the better fit depends on your goals.

NVAXRKLB
Market Cap
$1.30B$41.08B
Sector
HealthTechnology
52-Week High
$11.19$150.23
52-Week Low
$6.22$39.48
Enterprise Value
$800.50M$39.83B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.

Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.

Rocket Lab USA Inc

Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, with a bearish technical signal despite oscillators suggesting oversold conditions. The company reported a net loss of $198.21 million in 2025, though revenue grew to $601.80 million. Recent positive news includes a $266 million defense contract awarded on July 21, 2026, per Benzinga, providing a near-term catalyst amid broader sector volatility.

The outlook remains high-risk with negative profitability but strong analyst support; 75% recommend Buy with a $116.90 consensus target. Key risks include execution delays on the Neutron rocket and intense competition. Upside depends on contract execution and path to profitability, while downside stems from cash burn and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Rocket Lab USA Inc

Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.

Read more on RKLB